Kidney Cancer, Version 2.2020 Featured Updates to the NCCN Guidelines

被引：173

作者：

Motzer, Robert J. ^{[1
]}

Jonasch, Eric ^{[2
]}

Michaelson, M. Dror ^{[3
]}

Nandagopal, Lakshminarayanan ^{[4
]}

Gore, John L. ^{[5
]}

George, Saby ^{[6
]}

Alva, Ajjai ^{[7
]}

Haas, Naomi ^{[8
]}

Harrison, Michael R. ^{[9
]}

Plimack, Elizabeth R. ^{[10
]}

Sosman, Jeffrey ^{[11
]}

Agarwal, Neeraj ^{[12
]}

Bhayani, Sam ^{[13
,14
]}

Choueiri, Toni K. ^{[15
]}

Costello, Brian A. ^{[16
]}

Derweesh, Ithaar H. ^{[17
]}

Gallagher, Thomas H. ^{[5
]}

Hancock, Steven L. ^{[18
]}

Kyriakopoulos, Christos ^{[19
]}

LaGrange, Chad ^{[20
]}

Lam, Elaine T. ^{[21
]}

Lau, Clayton ^{[22
]}

Lewis, Bryan ^{[23
]}

Manley, Brandon ^{[24
]}

McCreery, Brittany ^{[5
]}

McDonald, Andrew ^{[4
]}

Mortazavi, Amir ^{[25
,26
]}

Pierorazio, Phillip M. ^{[27
]}

Ponsky, Lee ^{[28
,29
]}

Redman, Bruce G. ^{[7
]}

Somer, Bradley ^{[30
]}

Wile, Geoffrey ^{[31
]}

Dwyer, Mary A. ^{[32
]}

Hammond, Lydia J. ^{[32
]}

Zuccarino-Catania, Griselda ^{[32
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Massachusetts Gen Hosp, Canc Center

[4] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[5] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[6] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[7] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[9] Duke Canc Inst, Durham, NC USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[13] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[14] Washington Univ, Sch Med, St Louis, MO 14263 USA

[15] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[16] Mayo Clin, Canc Ctr, Rochester, MN USA

[17] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

[18] Stanford Canc Inst, Stanford, CA USA

[19] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[20] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[21] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[22] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[23] Kidney Canc Coalit, Philadelphia, PA USA

[24] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[25] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[26] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA

[27] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[28] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[29] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[30] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[31] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[32] Natl Comprehens Canc Network, Plymouth Meeting, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2019年 / 17卷 / 11期

关键词：

RENAL-CELL CARCINOMA; RADIOSURGERY ONCOLOGY CONSORTIUM; MICROVASCULAR TUMOR INVASION; TNM STAGING SYSTEM; INTERFERON-ALPHA; DOSE INTERLEUKIN-2; PHASE-III; CLASSIFICATION; THERAPY; SIZE;

D O I：

10.6004/jnccn.2019.0054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-line systemic therapy options for patients with advanced clear cell renal cell carcinoma.

引用

页码：1279 / 1285

页数：7

共 34 条

[1] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Choueiri, Toni K.
Halabi, Susan
Sanford, Ben L.
Hahn, Olwen
Michaelson, M. Dror
Walsh, Meghara K.
Feldman, Darren R.
Olencki, Thomas
Picus, Joel
Small, Eric J.
Dakhil, Shaker
George, Daniel J.
Morris, Michael J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) : 591 - +
[2] Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor
Dall'Oglio, Marcos F.
Antunes, Alberto A.
Sarkis, Alvaro S.
Crippa, Alexandre
Leite, Katia R.
Lucon, Antonio Marmo
Srougi, Miguel
[J]. BJU INTERNATIONAL, 2007, 100 (03) : 552 - 555
[3] Microvascular tumor invasion, tumor size and Fuhrman grade:: A pathological triad for prognostic evaluation of renal cell carcinoma
Dall'Oglio, Marcos F.
Ribeiro Filho, Leopoldo Alves
Antunes, Alberto A.
Crippa, Alexandre
Nesrallah, Luciano
Goncalves, Pierre D.
Leite, Katia R. M.
Srougi, Miguel
[J]. JOURNAL OF UROLOGY, 2007, 178 (02) : 425 - 428
[4] Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma
Ficarra, V
Schips, L
Guillé, F
Li, GR
De la Taille, A
Galetti, TP
Cindolo, L
Novara, G
Zigeuner, RE
Bratti, E
Tostain, J
Altieri, V
Abbou, CC
Artibani, W
Patard, JJ
[J]. CANCER, 2005, 104 (05) : 968 - 974
[5] Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort
Frank, I
Blute, ML
Leibovich, BC
Cheville, JC
Lohse, CM
Zincke, H
[J]. JOURNAL OF UROLOGY, 2005, 173 (06) : 1889 - 1892
[6] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Heng, Daniel Y. C.
Xie, Wanling
Regan, Meredith M.
Warren, Mark A.
Golshayan, Ali Reza
Sahi, Chakshu
Eigl, Bernhard J.
Ruether, J. Dean
Cheng, Tina
North, Scott
Venner, Peter
Knox, Jennifer J.
Chi, Kim N.
Kollmannsberger, Christian
McDermott, David F.
Oh, William K.
Atkins, Michael B.
Bukowski, Ronald M.
Rini, Brian I.
Choueiri, Toni K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) : 5794 - 5799
[7] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Hudes, Gary
Carducci, Michael
Tomczak, Piotr
Dutcher, Janice
Figlin, Robert
Kapoor, Anil
Staroslawska, Elzbieta
Sosman, Jeffrey
McDermott, David
Bodrogi, Istvan
Kovacevic, Zoran
Lesovoy, Vladimir
Schmidt-Wolf, Ingo G. H.
Barbarash, Olga
Gokmen, Erhan
O'Toole, Timothy
Lustgarten, Stephanie
Moore, Laurence
Motzer, Robert J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) : 2271 - 2281
[8] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
Hutson, Thomas E.
Lesovoy, Vladimir
Al-Shukri, Salman
Stus, Viktor P.
Lipatov, Oleg N.
Bair, Angel H.
Rosbrook, Brad
Chen, Connie
Kim, Sinil
Vogelzang, Nicholas J.
[J]. LANCET ONCOLOGY, 2013, 14 (13) : 1287 - 1294
[9] Prognostic impact of tumor size on pT2 renal cell carcinoma: An international multicenter experience
Klatte, Tobias
Patard, Jean-Jacques
Goel, Rakhee H.
Kleid, Mark D.
Guille, Francois
Lobel, Bernard
Abbou, Clement-Claude
De La Taille, Alexandre
Tostain, Jacques
Cindolo, Luca
Altieri, Vincenzo
Ficarra, Vincenzo
Artibani, Walter
Prayer-Galetti, Tommaso
Allhoff, Ernst Peter
Schips, Luigi
Zigeuner, Richard
Figlin, Robert A.
Kabbinavar, Fairooz F.
Pantuck, Allan J.
Belldegrun, Arie S.
Lam, John S.
[J]. JOURNAL OF UROLOGY, 2007, 178 (01) : 35 - 39
[10] Prognostic relevance of tumour size in T3a renal cell carcinoma: A multicentre experience
Lam, John S.
Klatte, Tobias
Patard, Jean-Jacques
Goel, Rakhee H.
Guille, Francois
Lobel, Bernard
Abbou, Clement-Claude
De La Taille, Alexandre
Tostain, Jacques
Cindolo, Luca
Altieri, Vincenzo
Ficarra, Vincenzo
Artibani, Walter
Prayer-Galetti, Tommaso
Schips, Luigi
Zigeuner, Richard
Pantuck, Allan J.
Figlin, Robert A.
Belldegrun, Arie S.
[J]. EUROPEAN UROLOGY, 2007, 52 (01) : 155 - 162

← 1 2 3 4 →